as of February 2021
Pre-clinical
![]() |
Phase II
pilot ![]() |
Phase III
pivotal or registration ![]() |
FDA Approved
![]() |
|
---|---|---|---|---|
Recurrent Glioblastoma | ||||
Newly Diagnosed Glioblastoma | ||||
Brain Metastasis | ||||
Non-small Cell Lung Cancer | ||||
Pancreatic Cancer | ||||
Ovarian Cancer | ||||
Mesothelioma | ||||
Liver Cancer | ||||
Gastric Cancer | ||||
Trial ongoing
Trial complete
|
Pre-clinical
We sponsor clinical trials of Tumor Treating Fields in several cancer types. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov.
Additional investigator-sponsored trials are also ongoing. For the most up-to-date clinical trial information, including protocol details, please visit the U.S. National Institutes of Health’s website at clinicaltrials.gov.
This information is for medical, and scientific and educational purposes only. Tumor Treating Fields is experimental for the treatment of patients with brain metastases, ovarian carcinoma, pancreatic adenocarcinoma, mesothelioma and non-small cell lung cancer. Tumor Treating Fields has not been approved by the U.S. Food and Drug Administration for commercial use in these indications. Limited by federal law to investigational use only.